Clene Inc. (BOATS:CLNN) Financings
Financings
| Raise | Date |
|---|---|
| Registered direct offering of common stock Closed: US$4M raised · US$3.28 a share Buyers: David Matlin (Led the offering); Kensington Capital Holdings Insiders: Led by the Chairman of the Board, David Matlin, alongside the Chief Executive Officer and other existing shareholders including insiders Use of proceeds: Fund operations through mid-first quarter 2027, beyond the potential FDA decision on accepting the CNM-Au8 NDA for review | Sep 21, 2026 |
| Registered direct offering of common stock Announced: about US$7M · US$7 a share · Canaccord Genuity LLC Dealers: Canaccord Genuity LLC (lead) Use of proceeds: General corporate purposes, NDA filing for CNM-Au8, expanded access and Phase 3 trial, manufacturing expansion, commercialization and early-stage R&D | May 5, 2026 |
| Registered direct offering of common stock with Series A and Series B warrants Announced: about US$28M · US$6.5 a share · Warrants at US$6 · BTIG, LLC Dealers: BTIG, LLC (lead) Buyers: Boxer Capital; Coastlands Capital; Vivo Capital Insiders: Offering priced above market to new, existing and insider investors, including other current insider investors Use of proceeds: Fund operations through potential FDA NDA acceptance and approval and commercialization of CNM-Au8 in ALS | Jan 9, 2026 |
| Not stated Closed: US$1.2M raised Use of proceeds: Fund operations into the second quarter of 2026 | Nov 13, 2025 |
| Equity Closed: US$1.9M raised Use of proceeds: To fund operations into the first quarter of 2026 | Aug 14, 2025 |
| Convertible debt facility Made bigger: US$1.5M Use of proceeds: To fund operations into the first quarter of 2026 | Aug 14, 2025 |
| Secured, partially convertible note Announced: US$10M Insiders: The note was signed with three entities, all of which are affiliated with Clene Use of proceeds: Repay the remaining Avenue Capital senior loan and extend cash runway to generate data for the CNM-Au8 ALS drug application | Dec 19, 2024 |